

#### INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7:
A61F 2/28, A61L 27/00
A1
(11) International Publication Number: WO 00/45747
(43) International Publication Date: 10 August 2000 (10.08.00)

(21) International Application Number: PCT/US99/02561

(22) International Filing Date: 5 February 1999 (05.02.99)

(71) Applicant: OSTEOTECH, INC. [US/US]; 51 James Way, Eatontown, NJ 07724 (US).

(72) Inventors: BOYCE, Todd, M.; 515 Wellington Place, Aberdeen, NJ 07747 (US). MANRIQUE, Albert; 8 Winthrop Drive, Manalapah, NJ 07726 (US). SCARBOROUGH, Nelson, L.; 47 Lambert Johnson Drive, Ocean, NJ 07712 (US). RUSSELL, James, L.; 57 Paag Circle, Little Silver, NJ 07737 (US).


(74) Agents: DILWORTH, Peter, G. et al.; Dilworth & Barrese, 333
Earle Ovington Boulevard, Uniondale, NY 11553 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, IP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

(54) Title: BONE-DERIVED IMPLANT FOR LOAD-SUPPORTING APPLICATIONS



(57) Abstract

A bone-derived implant (20) is provided which is made up of one or more layers (22, 23) of fully mineralized or partially demineralized cortical bone and, optionally, one or more layers (22, 23) of some other material. The layers (22, 23) constituting the implant (20) are assembled into a unitary structure to provide an implant (20) exhibiting good overall load-supporting properties.

# FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Scnegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
ΑZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
ВА	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo.
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	ΙE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KC	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuha	KZ	Kazakstan	RO	Romenia		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

# Description

HIS PAGE BLANK (USPTO)

#### BONE-DERIVED IMPLANT FOR LOAD-SUPPORTING APPLICATIONS

#### **BACKGROUND OF THE INVENTION**

Technical Field

The present invention relates to a bone-derived implant fabricated at least in part from strength-imparting cortical bone and intended for use in the repair, replacement and/or augmentation of various portions of animal or human skeletal systems. More particularly, this invention relates to a bone-derived implant which is made up of two or more layers at least one of which is fully mineralized or partially demineralized cortical bone and, optionally, one or more layers fabricated from some other material. The individual layers constituting the implant are assembled into a unitary structure capable of supporting loads.

#### Description of the Related Art

The use of autograft bone, allograft bone or xenograft bone is well known in both human and veterinary medicine. See Stevenson et al., *Clinical Orthopedics and Related Research*, 323, pp. 66-74 (1996). In particular, transplanted bone is known to provide support, promote healing, fill bony cavities, separate bony elements such as vertebral bodies, promote fusion and stabilize the sites of fractures. More recently, processed bone has been developed into shapes for use in new surgical applications, or as new materials for implants that were historically made of non-biologically derived materials.

5		U.S. Patent No. 4,678,470 describes a non-layered bone grafting material
		produced from bone by a process which includes tanning with glutaraldehyde. The
40		bone may be pulverized, used as a large block or machined into a precise shape.
10		The tanning stabilizes the material and also renders it non-antigenic. The bone
	5	material may also be demineralized.
15		The use of a continuous sheet of demineralized bone or partially
		demineralized bone is described in U.S. Patent No. 5,556,430; however, the sheet
		must be sufficiently flexible, therefore sacrificing strength, in order to conform to
20	•	the skeletal site to which it is applied.
	10	The surgically implantable sheet described in U.S. Patent No. 5,507,813 is
25		formed from elongate bone particles, optionally demineralized, containing
25		biocompatible ingredients, adhesives, fillers, plasticizers etc.
		U.S. Patent No. 4,932,973 discloses an artificial organic bone matrix with
30		holes or perforations extending into the organic bone matrix. These holes or
	15	perforations are indicated to be centers of cartilage and bone induction following
		implantation of the bone matrix.
35		U.S. Patent No. 4,394,370 discloses a one-piece sponge-like bone graft
		material fabricated from fully demineralized bone powder or micro particulate
40		bone, and reconstituted collagen. The sponge-like graft is optionally cross-linked
	20	with glutaraldehyde.
45		

50

55

-2-

Another one-piece porous implant is described in U.S. Patent No.

5,683,459. The implant is made up of a biodegradable polymeric macrostructure,

which is structured as an interconnecting open cell meshwork, and a biodegradable

polymeric microstructure composed of chemotactic ground substances such as

5

10

15

20

25

30

35

40

45

hyaluronic acid.

5

10

15

20

#### SUMMARY OF THE INVENTION

The present invention provides a long felt need in the field by providing a bone-derived implant capable of supporting loads and, in a preferred embodiment, through its bone healing activity and ability to incorporate medically/surgically useful substances at a surgical site to promote and/or accelerate new bone growth.

It is therefore an object of the present invention to provide a bone-derived implant made up of a plurality of superimposed layers, fixed to each other into a unitary structure, and possessing compression strength characteristics approximating those of natural bone.

It is another object of the invention to provide a bone implant possessing a network of pores, apertures, perforations, channels or spaces which permits and encourages penetration by endogenous and exogenous bone healing materials and blood supply, and simultaneously provides a means for incorporating one or more bone healing substances.

It is yet a further object of the present invention to provide a bone-derived implant which can be fashioned into a variety of shapes and sizes which are not

-3-

50

limited by constraints imposed by the normal anatomical sizes and/or types of donor bone which are available for the construction of the implant.

In keeping with these and other objects of the invention, there is provided a bone-derived implant which comprises a plurality of superimposed layers assembled into a unitary structure, at least one layer in the structure being a compression-strength imparting layer fabricated from nondemineralized cortical bone or partially demineralized cortical bone.

The bone-derived implant of the present invention possesses a significant advantage over prior art bone and bone-derived implants in its ability to approximate the mechanical strength characteristics of natural bone and to permit gradual transfer of load-bearing support therefrom to newly formed bone tissue over time.

Another important advantage of the bone-derived implant herein over prior art implants lies in its ability to function as a carrier for, and effectively incorporate, one or more medically/surgically useful substances that promote new bone growth and/or accelerate healing.

The term "osteogenic" as used herein shall be understood to refer to the ability of a substance to induce new bone formation via the participation of living cells from within the substance.

The term "osteoconductive" as used herein shall be understood to refer to the ability of a substance or material to provide biologically inert surfaces which are receptive to the growth of new host bone.

The term "osteoinductive" as used herein shall be understood to refer to the 5 ability of a substance to recruit cells from the host which have the potential for repairing bone tissue. 10 BRIEF DESCRIPTION OF THE DRAWINGS Various embodiments are described below with reference to the drawings 5 15 wherein: FIG. 1 is a cross-sectional view of bone from the diaphyseal region which 20 has been sliced longitudinally into several cortical bone layers; FIG. 2 is an enlarged perspective view of a bone-derived implant of the invention possessing layers of fully mineralized cortical bone alternating with 10 25 layers of partially and/or fully demineralized cortical bone; FIG. 3 is a partial view of the human vertebral column showing a dowelshaped bone-derived implant of the invention installed at an intervertebral site; 30 FIG. 4 is a view of the human skull showing a bone-derived implant of the invention fashioned as a zygomatic bone replacement; 15 35 FIG. 5 is an enlarged perspective view of a lattice-like section of bonederived implant; and, FIG. 6 is a partial view of the human vertebral column showing installation 40 of the bone-derived implant of Fig. 5 at an intervertebral site. 45

-5-

5

#### DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The bone-derived implant of the present invention comprises at least two superimposed layers at least one of the layers being a compression strengthimparting layer derived from nondemineralized cortical bone or cortical bone which has been only partially demineralized. When present as a compression strength-imparting layer, a partially demineralized cortical bone layer should exhibit a fairly high percentage of the compression strength of a comparable layer of nondemineralized cortical bone, e.g., preferably at least about 40, more preferably at least about 50 and still more preferably at least about 60 percent of such strength. Layers of partially demineralized cortical bone which exhibit significantly less than about 40 percent of the compression strength of a comparable layer of fully mineralized cortical bone can optionally be utilized in the bone-derived implant but in some capacity other than a load-bearing one. Depending on the thickness of the layers, there can be anywhere from 2 to about 200 layers overall in the bone-derived implant. The bone-derived implant can include layers of varying thicknesses, e.g., the compression strength-imparting layer(s) can be considerably thicker or thinner than any optional layer(s) that may be present. Thicknesses ranging from about 0.5 to about 20, and preferably from about 1.5 to about 15mm can advantageously be used. In general, the number and thickness of the compression-strength imparting layers in a given bone-derived implant will be such as to provide an overall compression strength for the implant of from about 25 to about 250, and preferably from about 100 to about 200 MPa.

<u>3</u>5

The sources of cortical bone for the bone-derived implant of this invention are preferably allogenic but also include xenogenic sources such as bovine and porcine bone. Where partially or fully demineralized cortical bone is utilized, such bone can be obtained employing known demineralization techniques, e.g., those employing strong acids such as hydrochloric acid as described in Reddi et al., *Proc. Nat. Acad. Sci.* 69, pp. 1601-5 (1972), herein incorporated by reference. The extent of demineralization is a function of the strength of the acid solution, the shape of the bone and the duration of the demineralization treatment. Reference in this regard may be made to Lewandrowski et al., *J. Biomed Materials Res*, 31, pp365-372 (1996), also incorporated herein by reference. The use of partially or fully demineralized bone can be beneficial herein since such substances exhibit greater initial osteogenic and/or osteoinductive activity than fully mineralized bone.

The compression strength-imparting layer(s) of the bone-derived implant can be provided as monolithic sections of bone or as multi-sectional layers built up from two or more subsections, e.g., joined to each other in edge-to-edge fashion in a manner which is analogous to planking. In this way, relatively large compression strength-imparting layers can be constructed from smaller bone sections to provide an implant whose overall size is not limited by the size and/or shape of the cortical bone which is available for its construction.

Assembling the superimposed layers into a strong unitary structure can be accomplished by a variety of means/procedures, e.g., application of known and conventional biologically compatible adhesives such as the cyanoacrylates; epoxy-

based compounds, dental resin sealants, dental resin cements, glass ionomer cements, polymethyl methacrylate, gelatin-resorcinol-formaldehyde glues, collagen-based glues, inorganic bonding agents such as zinc phosphate, magnesium phosphate or other phosphate-based cements, zinc carboxylate, etc., and proteinbased binders such as fibrin glues and mussel-derived adhesive proteins; the use of mechanical fasteners such as pins, screws, dowels, etc., which can be fabricated from natural or synthetic materials and bioabsorbable as well as nonbioabsorbable materials; laser tissue welding; and, ultrasonic bonding. If desired, the layers of the bone-derived implant can be provided with mechanically interengaging features, e.g., tongue-and-groove or mortise-and-tenon elements, to facilitate their assembly into the final product and/or to fix the layers to each other in a more secured fashion. In addition to its compression strength-imparting fully mineralized or partially mineralized cortical bone layers, the bone-derived implant of this invention can optionally possess one or more layers formed from one or more other materials. For example, these optional layers can be based on or include highly or fully demineralized bone, graphite or pyrolytic carbon, a mineral material such as hydroxyapatite, tricalcium phosphate, bioglass or other bioceramic or natural or synthetic polymers, e.g., bioabsorbable materials such as starches, polyglycolide, polylactide, glycolide-lactide copolymer, and the like, and nonbioabsorbable polymers such as polymethyl methacrylate, polytetrafluoroethylene, polyurethane, polyethylene and nylon.

45

50

-8-

If desired, the compression strength axis of one or more compression strength-imparting layers can be offset relative to the compression strength axis of one or more of the other compression strength-imparting layers in an arrangement much like that of plywood. For example, compression strength axes of alternating compression strength-imparting layers can be offset by up to 90° from the compression strength axes of the other compression strength-imparting layers in the implant in order to distribute the overall load-supporting capacity of the implant in mutually transverse directions.

Bone-derived implants of any desirable size and/or configuration can be provided, e.g., by machining or other mechanical shaping operations such as press-molding. Computerized modeling of a specific implant followed by computerized control of the shaping of the implant can be used to provide an intricately shaped bone-derived implant which is custom-fitted to the intended site of application with great precision.

The bone-derived implant can possess one or more cavities which, if desired, can communicate with the surface of the implant through pores, apertures, perforations or channels provided for this purpose and ranging in average diameter from a few microns to several millimeters. Such cavities and their associated pores, apertures, perforations and channels can be partially or completely filled with one or more medically/surgically useful substances which promote or accelerate new bone growth or bone healing due, e.g., to some osteogenic, osteoconductive and/or osteoconductive effect. Useful substances of this kind

-9-

which can be incorporated into the bone-derived implant of this invention include, e.g., collagen, insoluble collagen derivatives, etc., and soluble solids and/or liquids dissolved therein, e.g., antiviral agents, particularly those effective against HIV and hepatitis; antimicrobials and/or antibiotics such as erythromycin, bacitracin, neomycin, penicillin, polymyxin B, tetracyclines, viomycin, chloromycetin and streptomycins, cefazolin, ampicillin, azactam, tobramycin, clindamycin and gentamicin, etc.; biocidal/biostatic sugars such as dextroal, glucose, etc.; amino acids, peptides, vitamins, inorganic elements, co-factors for protein synthesis; hormones; endocrine tissue or tissue fragments; synthesizers; enzymes such as collagenase, peptidases, oxidases, etc.; polymer cell scaffolds with parenchymal cells; angiogenic drugs and polymeric carriers containing such drugs; collagen lattices; antigenic agents; cytoskeletal agents; cartilage fragments, living cells such as chondrocytes, bone marrow cells, mesenchymal stem cells, natural extracts, tissue transplants, bone, demineralized bone powder (or "demineralized bone matrix" as it may also be referred to), autogenous tissues such as blood, serum, soft tissue, bone marrow, etc.; bioadhesives, bone morphogenic proteins (BMPs), transforming growth factor (TGF-beta), insulin-like growth factor (IGF-1); growth hormones such as somatotropin; bone digestors; antitumor agents; immuno-suppressants; permeation enhancers, e.g., fatty acid esters such as laureate, myristate and stearate monoesters of polyethylene glycol, enamine derivatives, alpha-keto aldehydes, etc.; and, nucleic acids. These and similar medically/surgically useful substances can be incorporated into the bone-

45

40

20

-10-

5

10

5

10

15

20

15

20

25

30

35

40

45

derived implant of this invention or any of its constituent layers during any stage of the assembly of the implant. Suitable methods of incorporation include coating, immersion saturation, packing, etc. The amounts of medically/surgically useful substances utilized can vary widely with optimum levels being readily determined in a specific case by routine experimentation.

The bone-derived implant herein is intended to be applied at a bone defect site, e.g., one resulting from injury, defect brought about during the course of surgery, infection, malignancy or developmental malformation. The bone-derived implant, suitably sized and shaped as required, can be utilized as a graft or replacement in a wide variety of orthopaedic, neurosurgical and oral and maxillofacial surgical procedures such as the repair of simple and compound fractures and non-unions, external and internal fixations, joint reconstructions such as arthrodesis, general arthroplasty, cup arthroplasty of the hip, femoral and humeral head replacement, femoral head surface replacement and total joint replacement, repairs of the vertebral column including spinal fusion and internal fixation, tumor surgery, e.g., deficit filling, discectomy, laminectomy, excision of spinal cord tumors, anterior cervical and thoracic operations, repair of spinal injuries, scoliosis, lordosis and kyphosis treatments, intermaxillary fixation of fractures, mentoplasty, temporomandibular joint replacement, alveolar ridge augmentation and reconstruction, inlay bone grafts, implant placement and revision, sinus lifts, etc. Specific bones which can be repaired or replaced with the bone-derived implant herein include the ethmoid, frontal, nasal, occipital,

-11-

50

parietal, temporal, mandible, maxilla, zygomatic, cervical vertebra, thoracic vertebra, lumbar vertebra, sacrum, rib, sternum, clavicle, scapula, humerus, radius, ulna, carpal bones, metacarpal bones, phalanges, ilium, ischium, pubis, femur, tibia, fibula, patella, calcaneus, tarsal and metatarsal bones.

Referring to the drawings, as shown in FIG. 1, the cortical portion of bone 10 taken from the diaphyseal region is cut into cortical bone layers 11 of varying width by slicing the bone longitudinally. If desired, cortical bone layers 11 can be further cut to uniform size and shape as in bone layers 22 of the implant 20 shown in FIG. 2.

FIG. 2 illustrates a bone-derived implant 20 comprising alternating layers of fully mineralized cortical bone 22 and partially demineralized cortical bone 23. Alternatively, one or more layers 23 can be made from a material other than partially demineralized bone such as fully demineralized bone or mineral substances such as hydroxyapatite. The total thickness of the bone implant will ordinarily be at least about 5, and preferably at least about 10, mm. Bone-derived implant 20 can be cut, machined, and/or otherwise formed into any other desired shape or dimension for implantation into a body. For example, a substantially cylindrically shaped bone implant can be made for use as a long bone segment replacement, e.g., for a femur. To form a cylinder, a substantially square or rectangular bone-derived implant can be shaped on a lathe to the required diameter. A cavity can be formed by removing material with, for example, a

-12-

drill, or, alternatively, a cavity can be formed by assembling appropriately configured layers.

As shown in FIG. 3, cylindrical or dowel-shaped bone-derived implant 30 is shown inserted at the intervertebral fibrocartilage site on the anterior side of vertebral column 31.

In FIG. 4, zygomatic bone-derived implant 40 is sized and shaped to form part of the zygomatic arch and part of the interior orbit of skull 41.

<sub>\_</sub>35

As shown in the sectional view of FIG. 5, bone-derived implant 50 is built up from elongate sections 51 of compression strength-imparting fully mineralized or partially demineralized cortical bone of uniform square cross section and arranged in lattice-wise fashion employing a suitable adhesive, e.g., of the cyanoacrylate variety. Because of the open structure of implant 50 resulting from the pattern of longitudinal channels 52 and transverse channels 53, the implant permits the vascular penetration or host bone ingrowth therein and/or the diffusion of one or more medically/surgical useful substances therefrom. Vertical channels in the lattice-like array can, if desired, be partially or completely occupied by appropriately-configured and dimensioned sections 54 fabricated from fully mineralized or partially demineralized cortical bone as in cortical bone sections 51 or from any of the other substances disclosed herein. Fully assembled bone implant 50 is shown installed in intervertebral space 61 of vertebral column 60 of FIG. 6.

-13-

The following examples are further illustrations of the bone-derived implant of this invention.

#### EXAMPLE 1

A cortical section of bone from the diaphyseal region was cut in the longitudinal direction while continuously wetted with water into approximately 1.5 mm thick layers using a diamond-bladed saw. The layers were then frozen to -70C and freeze-dried for 48 hours. The layers were then assembled with cyanoacrylate adhesive and held in a clamp for two hours while the adhesive set. The resulting multilayered unitary structure was cut on a band saw and shaped by grinding and machining with a hand-held motorized shaping tool to provide a shaped bone implant.

#### **EXAMPLE 2**

A section of cortical bone from the diaphyseal region was saw-cut as in Example 1 into approximately 1.5 mm thick layers. Half of the slices were fully demineralized in a known manner employing 0.6N HCl acid. All of the layers were then assembled with cyanoacrylate adhesive with layers of fully mineralized bone alternating with layers of fully demineralized bone. A bone-derived implant of this type is illustrated in FIG. 2.

-14-

EXAMPLE 3

A diaphyseal bone segment about 50 mm in length was saw-cut while continuously wetted with water to provide elongate cortical bone sections of uniform, square cross section. The elongate bone sections were then assembled with cyanoacrylate adhesive to provide a lattice-like structure in which layers of spaced-apart bone sections were arranged transversally with respect to each other. A section of bone-derived implant of this type is illustrated in FIG. 5.

.

-15-

# Claims

THIS PAGE BLANK (USPTO)

WHAT	IS	CL	ATN	<b>IED</b>	IS:

1.	A bone-derived implant which comprises a plurality of
superimposed	layers assembled into a unitary structure, at least one layer in the
structure bein	g a compression strength-imparting layer fabricated from
nondemineral	ized cortical bone or partially demineralized cortical bone.

- The bone-derived implant of Claim 1 wherein the partially demineralized bone layer exhibits not less than about 40 percent of the compression strength of a comparable layer of fully mineralized bone.
- 3. The bone-derived implant of Claim 1 wherein the partially demineralized bone layer exhibits not less than about 50 percent of the compression strength of a comparable layer of fully mineralized bone.
- 4. The bone-derived implant of Claim 1 wherein the partially demineralized bone layer exhibits not less than about 60 percent of the compression strength of a comparable layer of fully mineralized bone.
- 5. The bone-derived implant of Claim 1 possessing at least two compression strength-imparting layers.

WO 00/45747	PCT/US99/0256

5		6.	The bone-derived implant of Claim 1 possessing a total thickness of
		at least about	5 mm.
10		7.	The bone-derived implant of Claim 1 possessing a total thickness of 10 mm.
15	. 5	8.	The bone-derived implant of Claim 1 possessing a cross section for
	-	at least a por	tion of its length which is, or approximates, a circle, oval or polygon,
20		the implant o	ptionally possessing a cavity for at least a portion of its length.
25		9.	The bone-derived implant of Claim 8 wherein pores, apertures, or channels provide communication between the cavity and the surface
	10	of the bone.	
30		10.	The bone-derived implant of Claim 1 configured as a graft.
35		11.	The bone-derived implant of Claim 1 configured as a replacement section thereof.
40		12.	The bone-derived implant of Claim 11 configured as an
	15	intervertebral	insert, a long bone, a cranial bone, a bone of the pclvis, or a bone
45		of the hand o	r foot or a section of any of the foregoing.
			-17-

		101/00///0201
5		13. The bone-derived implant of Claim 1 wherein at least one
		mechanical strength-imparting layer is provided as a monolithic bone section.
10		14 The bear desired implement of Claim 1 wherein at least and
		14. The bone-derived implant of Claim 1 wherein at least one
		mechanical strength-imparting layer is provided as a multi-sectional bone section
15	5	wherein subsections of bone constituting the section are joined to each other in
		edge-to-edge fashion.
20		15. The bone-derived implant of Claim 1 possessing upper and lower
		major exposed surfaces, said surfaces being those of compression strength-
25		imparting layers.
23		
	10	16. The bone-derived implant of Claim 1 possessing at least one layer
30		fabricated in whole or in part from at least one material which is other than
		nondemineralized or partially demineralized cortical bone.
35	,	17. The bone-derived implant of Claim 16 wherein the material
		facilitates bone healing.
40	15	18. The bone-derived implant of Claim 17 wherein the material
		·
		possesses osteogenic, osteoconductive and/or osteoinductive activity.
45		

50

	WC	O 00/45747	FC1/U399/02501
5		19. The bone-derived implant of Claim 18 wherein the	e material is
		selected from the group consisting of partially demineralized bon	ie, substantially
		fully demineralized bone, growth factors, bone morphogenic pro	teins, bone
10		forming cells, precursor cells, genetic material, inorganic compo	unds and
	5	polymers.	
15			
		20. The bone-derived implant of Claim 1 wherein each	1 strength-
		imparting layer possesses the same or different average thickness	in the range of
20		from about 0.5 mm to about 20 mm.	
		$\cdot$	
25		21. The bone-derived implant of Claim 1 wherein each	layer possesses
	10	the same or different average thickness in the range of from about	it 1.5 mm to
		about 15 mm.	
30			
		22. The bone-derived implant of Claim 1 wherein the	compression
		strength axes of at least two consecutive compression strength-im	parting layers are
35		offset relative to each other.	
40	15	23. The bone-derived implant of Claim 1 wherein at le	ast two
		consecutive compression strength-imparting layers are each made	up of spaced-
		apart sections with the compression strength axes of the layers be	ing offset relative


		0 00,10,747
5		to each other in a lattice-like arrangement defining an array of channels in all three dimensions.
10		24. The bone-derived implant of Claim 23 wherein one or more vertical channels in the array is partially or completely occupied by one or more
15	5	appropriately configured and dimensioned sections of material.
20	·	25. The bone-derived implant of Claim 24 wherein the sections are fully mineralized bone or partially or fully demineralized bone.
25	10	26. The bone-derived implant of Claim 23 wherein at least one channel contains an osteogenic, osteoconductive and/or osteoinductive material.
30		27. The bone-derived implant of Claim 26 wherein the material is selected from the group consisting of partially demineralized bone powder,
35	15	substantially fully demineralized bone powder, growth factors, bone morphogenic proteins, bone forming cells or precursor cells, genetic material, and inorganic compounds or polymers.
40		
45		


50

5		28. The bone-derived implant of Claim 5 wherein the axis of one or more
		compression-strength axis of one or more compression strength-imparting layers is
		offset relative to the compression strength axis of one or more of the other
10		compression strength-imparting layers.
15	5	29. The bone-derived implant of Claim 1 having a compression strength
		of from about 25 to about 250 MPa.
20		30. The bone-derived implant of Claim 1 having a compression strength
		of from about 100 to about 200 MPa.
25		31. The bone-derived implant of Claim 1 possessing from 2 to about
	10	200 layers.
30		
		32. The bone-derived implant of Claim 47 possessing means for
		facilitating diffusion of bone healing material.
35		
		33. The bone-derived implant of Claim 32 wherein the means for
40		facilitating diffusion of bone healing material constitutes channels defined within
	15	one or more layers.
45		
		-21-
50		

WO 00/45747	PCT/US99/02561
TT U UU/43 /4 /	PC1/US99/U2561

5		34.	The bone-derived implant of Claim 1 fabricated in whole or in part
		from allogen	ic and/or xenogenic cortical bone.
10			
10		35.	The bone-derived implant of Claim 1 wherein the superimposed
		layers are ass	sembled with adhesive.
15			
	5	36.	The bone-derived implant of Claim 1 wherein the superimposed
		layers are ass	sembled with mechanical fasteners.
20		·	
25		•	
30			,
35			
40			
45			
70			
			-22-





SUBSTITUTE SHEET (RULE 26)




FIG. 3






FIG. 4

SUBSTITUTE SHEET (RULE 26)





SUBSTITUTE SHEET (RULE 26)

# INTERNATIONAL SEARCH REPORT

Interv Vital Application No PCT/US 99/02561

A. CLASS IPC 7	FICATION OF SUBJECT MATTER A61F2/28 A61L27/00	,				
According t	o International Patent Classification (IPC) or to both national classific	cation and IPC				
	SEARCHED					
IPC 7	ocumentation searched (classification system followed by classificat A61F					
Documenta	tion searched other than minimum documentation to the extent that	such documents are included in the fields se	earched			
Electronic o	lata base consulted during the international search (name of data b	ase and, where pradical, search terms used	)			
C. DOCUM	ENTS CONSIDERED TO BE RELEVANT					
Category *	Citation of document, with indication, where appropriate, of the re	elevant passages	Relevant to claim No.			
Y	WO 88 03417 A (MATERIAL CONSULTAI 19 May 1988 (1988-05-19) page 17, line 29 -page 18, line	1,5, 8-12,16, 31,34				
Y	4.6C,7B, GB 2 175 506 A (AMERICAN HOSPITA CORPORATION) 3 December 1986 (198	1,5, 8-12,16, 31,34				
Α	abstract; figures	19,25,27				
A	US 5 053 049 A (CAMPBELL) 1 October 1991 (1991-10-01) abstract	1	1			
A	US 5 348 788 A (WHITE) 20 September 1994 (1994-09-20) the whole document 	,	1,8,9,35			
	-	-/	····			
X Funt	ner documenta are listed in the continuation of box C.	X Patent family membors are listed in	л аппех.			
"A" documed consider of filling de "L" documed which citation "O" documed other n" P" documed "P" docu	nt which may throw doubts on priority claim(s) or is cited to establish the publication dale of another or other special reason (as specified) ent referring to an oral disclosure, use, exhibition or	"T" later document published after the international filing date or priority date and not in conflict with the epplication but clied to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered noval or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.  "A" document member of the same patent family				
Date of the	actual completion of the international search	Date of mailing of the international sea.	rch report			
	November 1999	10/11/1999				
Name and n	nating address of the ISA  European Patent Office, P.B. 5818 Patentiaen 2  NL - 2280 HV Rijswijk  Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  Fax: (+31-70) 340-3016	Authorized officer  Klein, C				

### INTERNATIONAL SEARCH REPORT

Inter anal Application No PCT/US 99/02561

Category *	tion) DOCUMENTS CONSIDERED TO BE RELEVANT  Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
arear.	Organous promittents and minoratori autora abbiodritate or mo totasana bassadas	
١	EP 0 621 018 A (KYOCERA CORPORATION) 26 October 1994 (1994-10-26) the whole document	1,12
A	DE 196 10 715 C (KIRSCH) 26 June 1997 (1997-06-26) abstract; figures	9,11
`	US 5 554 194 A (SANDERS) 10 September 1996 (1996-09-10) figure 10	12
E	US 5 899 939 A (BOYCE) 4 May 1999 (1999-05-04) the whole document	1-36
Α .	EP 0 505 634 A (KYOCERA CORPORATION) 30 September 1992 (1992-09-30)	
A	US 5 514 378 A (MIKOS) 7 May 1996 (1996-05-07)	
A	EP 0 649 640 A (BHC LABORATORIES) 26 April 1995 (1995-04-26)	
A	US 5 556 430 A (GENDLER) 17 September 1996 (1996-09-17) cited in the application	
A	US 4 394 370 A (JEFFRIES) 19 July 1983 (1983-07-19) cited in the application	

#### INTERNATIONAL SEARCH REPORT

.formation on patent family members

Inter Inal Application No PCT/US 99/02561

					T/US 99/0	
Patent docu cited in search		Publication date		Patent family member(s)		Publication date
WO 88034	17 A	19-05-1988	FI AT AU AU CA	864457 85225 606903 8235787 1297795	T B A	04-05-1988 15-02-1993 21-02-1993 01-06-1988 24-03-1992
			DE EP ES JP SU US	3784060 0289562 2005049 1501289 1769715 5084051	A A A T A	18-03-1993 09-11-1988 16-02-1989 11-05-1989 15-10-1992 28-01-1992
GB 21755	06 A	03-12-1986	US CA DE FR JP	4627853 1298935 3617897 2582517 62032965	A A A	09-12-1986 21-04-1992 04-12-1986 05-12-1986 12-02-1987
US 505304	49 A	01-10-1991	DE FR GB JP	3617898 2582516 2175807 62032966	A A,B	04-12-1986 05-12-1986 10-12-1986 12-02-1987
US 534878	38 A	20-09-1994	US EP JP US US	5455100 0647439 7171172 5487933 5728510	A A A	03-10-1995 12-04-1995 11-07-1995 30-01-1996 17-03-1998
EP 621018	3 А	26-10-1994	JP DE EP US US	6007388 69326440 0566427 5496372 5732469	D A A	18-01-1994 21-10-1999 20-10-1993 05-03-1996 31-03-1994
DE 196107	715 C	26-06-1997	AU WO EP	1923797 9734546 0888096	A	10-10-1997 25-09-1997 07-01-1999
US 555419	94 A	10-09-1996	CA EP	2175284 0747019		08-12-1996 11-12-1996
US 589993	39 A	04-05-1999	NONE			
EP 505634	1 A	30-09-1992	JP DE DE US US	4303444 69127354 69127354 5458643 5314478	D T A	27-10-1992 25-09-1997 22-01-1998 17-10-1995 24-05-1994
US 551437	'8 A	07-05-1996	NONE			
EP 649640	) A	26-04-1995	US CA	5522904 2130866		04-06-1996 14-04-1995
US 555643	30 A	17-09-1996	US US DE	5464439 5306304 69111021	4	 07-11-1995 26 <b>-</b> 04-1994 10-08-1995

# INTERNATIONAL SEARCH REPORT Inter 'nal Application No

			nation on patent family me	embers			Application No 99/02561
	itent document I in search report		Publication date	Pe	atent family nember(s)		Publication date
US	5556430	Α		EP ES	04839 20764	44 A 67 T	06-05-1992 01-11-1994
US	4394370	A	19-07-1983	US	44728	40 A	25-09-1984
							•
							•
						,	